Climb Bio, Inc. Common Stock · XNAS · 131 sessions on record
$11.47▼ −0.03 · −0.3%from $11.50 the session before · Sep 30, 2026 close · end of day
Open
$11.69
High
$11.93
Low
$11.32
Day's range
$0.615.3% of the previous close
VWAP
$11.50close −0.29% from it
Volume, shares
1.41M0.76× the 20-session average
Traded, $
$16.2M
Trades
13.1K110 shares per trade
Previous close
$11.50−0.03 to the close
Market cap
$658.8Mat the close of Sep 30
Day range25% of the way up
$11.32$11.93
52-week range43% of the way up
$6.22 Apr 7$18.33 Aug 25
−37% from the high · +84% from the low
Options
No listed options on CLYM
Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
consolidated · latest filed Aug 6, 2026 · SEC filings
Profit −$13.5M in the Jun 2026 quarter, consolidated.
Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of CLYM on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 6
—
—
−$13.5M
—
-0.18
0.0%S&P 500 +0.6% · −0.6 pp
Mar 2026filed Aug 6
—
—
−$13.7M
—
-0.20
0.0%S&P 500 +0.6% · −0.6 pp
Dec 2025filed Mar 5
—
—
−$17.5M
—
-0.25
—not reached
Sep 2025filed Nov 6
—
—
−$12.9M
—
-0.19
—not reached
Jun 2025filed Aug 6
—
—
−$8.7M
—
-0.13
0.0%S&P 500 +0.6% · −0.6 pp
Mar 2025filed Aug 6
—
—
−$20.8M
—
-0.31
0.0%S&P 500 +0.6% · −0.6 pp
Dec 2024filed Mar 25
—
—
−$8.4M
—
0.47
—not reached
Sep 2024filed Nov 6
—
—
−$8.9M
—
-0.13
—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of CLYM on the consolidated basis, summed from the quarters filed
Year
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
FY25to Dec 2025
—
—
−$59.9M
—
-0.88
FY24to Dec 2024
—
—
−$73.9M
—
-1.53
FY23to Dec 2023
—
—
−$35.1M
—
-1.30
FY22to Dec 2022
—
—
−$45.2M
—
-1.72
FY21to Dec 2021
—
—
−$47.5M
—
-4.24
Fundamentals
consolidated · filings to Jun 2026 · close $11.47 on Sep 30
2.8 times book value, market cap $658.8M.
Valuation
Market cap
$658.8Mon Sep 30
Price to earnings
—
Trailing EPS
$-0.82diluted · consolidated · four quarters to Jun 2026
Price to book
2.8consolidated · balance sheet to Jun 2026
Book value a share
$4.17consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-27%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
57.4Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$57.6Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
13F managers hold 190% of shares, RA CAPITAL MANAGEMENT, L.P. the largest at 39%, FMR LLC 24% and UBS Group AG 12%, as filed for the quarter to Jun 2026.
39.4%23.6%11.9%114.2%
RA CAPITAL MANAGEMENT, L.P. 39.4%
FMR LLC 23.6%
UBS Group AG 11.9%
Other 13F managers 114.2%
Held by 13F managers
190%of shares outstanding
Shares held
109M+67% on Mar 2026 among managers filing both
Managers holding
10775 a quarter earlier
Largest holder
39%RA CAPITAL MANAGEMENT, L.P.
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of CLYM
Manager
Shares
Of outstanding
Value
Change on quarter
RA CAPITAL MANAGEMENT, L.P.
22.6M
39%
$294.7M
unchanged
FMR LLC
13.6M
24%
$177.1M
+13.6M
UBS Group AG
6.81M
12%
$88.8M
+6.64M
BRAIDWELL LP
5.59M
9.7%
$73.0M
+2.54M
ADAGE CAPITAL PARTNERS GP, L.L.C.
5.01M
8.7%
$65.4M
—
BlackRock, Inc.
4.71M
8.2%
$61.4M
+3.91M
Cormorant Asset Management, LP
4.21M
7.3%
$54.9M
—
FRONTIER CAPITAL MANAGEMENT CO LLC
3.88M
6.8%
$50.6M
—
VANGUARD CAPITAL MANAGEMENT LLC
3.4M
5.9%
$44.3M
+1.04M
Woodline Partners LP
3.16M
5.5%
$41.3M
—
Insider tradesSEC Forms 3, 4 and 5 · the latest 7
No open-market insider buying or selling in the last 90 days.
CLYM insider trades
Insider
Trade
Shares
Price
Held after
Brennan AoifeDirector,Officer
sold · Jun 29, 2026
30,902
$13.17
87,731
Brennan AoifeDirector,Officer
exercised · Jun 27, 2026
68,750
—
118,633
Thomas Stephen BasilDirector
sold · Feb 25, 2026
33,687
$7.00
170,970
Thomas Stephen BasilDirector
sold · Feb 26, 2026
16,313
$7.01
154,657
Thomas Stephen BasilDirector
sold · Feb 12, 2026
90,000
$5.23
214,657
Thomas Stephen BasilDirector
sold · Feb 13, 2026
10,000
$5.81
204,657
RA Capital Healthcare Fund LPDirector,TenPercentOwner
bought · Jan 5, 2026
7,111
$3.50
3,403,429
Corporate actions
exchange records
No corporate action on record for CLYM yet.
Price history
131 sessions on record · to Sep 30 · end of day
CLYM is −22.6% over 20 sessions against the S&P 500's +0.1%, 37% below its 52-week high, realised volatility 66% annualised.
Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
Window
From $
CLYM %
S&P 500 %
Difference pp
120 sessionssince Apr 9
$8.05
▲ +42%
▲ +12%
+30
60 sessionssince Jul 7
$13.42
▼ −15%
▲ +2.0%
−17
20 sessionssince Sep 1
$14.82
▼ −23%
▲ +0.11%
−23
5 sessionssince Sep 23
$12.52
▼ −8.4%
▼ −0.67%
−7.7
1 sessionsince Sep 29
$11.50
▼ −0.26%
▼ −0.21%
−0.05
Averages of the closeclose against each average
5-session average
$11.65close −1.5% from it
20-session average
$13.73close −16% from it
50-session average
$14.13close −19% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.887.7% of the close
Average day's range, 20
$0.806.9% of the close
Volume against 20 sessions
0.76×1.41M vs 1.82M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
66%≈ ±4.1% a session · moved more than that on 7 of 20
Realised volatility, 60
75%≈ ±4.8% a session · moved more than that on 18 of 60
Beta to S&P 500, 60
0.65moved with S&P 500 on 32 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
7 up · 13 downof 20
Last 60 sessions
26 up · 33 downof 59
Best session, 250
▲ +18%May 5
Worst session, 250
▼ −12%Sep 23
Short-sale volume
25 sessions · to Sep 30, 2026
Short sales were 53% of reported volume on Sep 30, 2026, against 56% over the last 25 sessions.
Last 10 sessionsshare of the day's reported volume
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1768446
Sessions on record
131
Price source
End of day · delayed
Computed
2 Oct, 03:08 am IST
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.